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OBJECTIVE: We conducted a study to identify gender differences in factors associated with the first episode of
non-adherence in the 12 months following the first antiretroviral prescription.
METHODS: A concurrent prospective study of patients initiating antiretroviral therapy in Brazil was conducted
from 2001-2002. The self-reported measurement of adherence was defined as an intake of less than 95% of the
prescribed number of doses. Only the first occurrence of non-adherence was considered in this analysis. All
analyses were stratified by gender. A Cox proportional hazard model was used to estimate the risk of non-
adherence, and the time to non-adherence was estimated using the Kaplan-Meier method.
RESULTS: The cumulative incidence of non-adherence was 34.6% (29.7% and 43.9% among men and women,
respectively; p=0.010). Marital status (being married or in stable union; p=0.022), alcohol use in the month
prior to the baseline interview (p=0.046), and current tobacco use (p=0.005) increased the risk of non-
adherence among female participants only, whereas a self-reported difficulty with the antiretroviral treatment
was associated with non-adherence in men only. For both men and women, we found that a longer time
between the HIV test and first antiretroviral therapy prescription (p=0.028) also presented an increased risk of
non-adherence.
CONCLUSIONS: In this cohort study, the incidence of non-adherence was 1.5 times greater among women
compared to men. Our results reinforce the need to develop interventions that account for gender differences
in public referral centers. Additionally, we emphasize that, to achieve and maintain appropriate adherence
levels, it is important to understand the barriers to seeking and utilizing health care services.
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& INTRODUCTION
A broad consensus in the literature supports the necessity
of maintaining high rates of adherence to antiretroviral
therapy (ART) to achieve viral suppression (1); to prevent
the emergence of resistant strains, disease progression and
HIV transmission (2-3); and to improve quality of life (4).
Despite the necessity of high adherence to ART, findings
from a meta-analysis including 84 observational studies
suggested that the mean proportion of patients reporting an
intake of $90% prescribed pills is 62% worldwide (5).
Although it is not completely clear which individual and/
or structural factors are associated with greater rates of
adherence, evidence from the literature indicates that
gender plays an important role in determining differences
in HIV therapeutics. For example, women seem to delay
initiation of ART more frequently (6), to have higher
incidence of treatment interruption (7), to experience more
side effects (8), and to have more viral rebound after initial
suppression than men (9); furthermore, women appear to
metabolize antiretroviral (ARV) drugs differently than men
(10).
There is also evidence that women living with HIV face
different barriers to adherence than do their male counter-
parts, including depression, stress, stigmatization, and
specific social roles related to gender. Furthermore,
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researchers suggest that, among females living with HIV,
substance abuse and alcohol use are predictive of poor
adherence (11-12). However, inconsistencies remain regard-
ing the association between gender and non-adherence. One
possible explanation is that this relationship may be
confounded by unexamined social or behavioral factors.
Furthermore, these associations have not been extensively
studied in developing countries (13).
We have previously reported data from a cohort study on
adherence to ART (ATAR Project) in which multivariate
analyses indicated that unemployment, alcohol use, adverse
reactions, number of pills, changes in ART regimen, and a
longer duration between the HIV test result and the first
prescription were predictors of non-adherence. Gender was
associated with non-adherence in the univariate analysis
only (14). However, an improved understanding of gender
differences in ART adherence may contribute to the
development of more effective gender-based interventions
that can potentially reduce therapy failure during follow-
up. Thus, the aim of this study was to identify gender
differences in factors associated with the first episode of
non-adherence in the 12 months following the first ARV
prescription in AIDS public referral centers in Brazil.
& METHODS
This concurrent prospective analysis is part of the ATAR
Project, a cohort study conducted during 2001-2002, for
which the main objective was to determine the incidence
and determinants of non-adherence to ART among people
living with HIV (PLHIV). Participants were adult ($18
years old) patients initiating treatment at two public AIDS
referral centers in Belo Horizonte, Brazil, a large urban area
with approximately 2.5 million inhabitants (14). Participants
were assessed immediately after receiving their first ARV
drugs from the pharmacies at each center (baseline inter-
view) and in the first, fourth, and seventh months after
initiating therapy (follow-up visits). The maximum follow-
up period was 12 months. This analysis aimed at assessing
the first episode of non-adherence among patients who
returned for at least one follow-up visit during the study
period. Ethical approval and consent forms were obtained.
Baseline data included sociodemographic, clinical, and
behavioral characteristics, whereas adherence to ART was
evaluated at each follow-up visit. Additionally, quality of
life and presence of anxiety and depression symptoms were
assessed at baseline and at the second follow-up visit.
For the purposes of these analyses, the exposure variables
have been grouped as follows: (i) sociodemographics (i.e.,
age, race, education, marital status, income, job schedule);
(ii) behavioral factors (i.e., HIV status disclosure and
alcohol, illicit drug, and tobacco use); (iii) health services-
related variables (i.e., recruitment site, difficulty in search-
ing for HIV service, use of more than one health service for
HIV care, psychological support, and understanding of
medical and pharmaceutical counseling related to ARV
agents); and (iv) clinical and treatment-related factors (i.e.,
number of pills per day, self-reported difficulty of ART,
clinical classification, TCD4+ lymphocyte count, adverse
reactions, time between HIV test result or first medical visit
to ARV prescription, self-perceived quality of life, and
presence of anxiety and depression symptoms). The clinical
and immunological data were extracted from medical
charts, which were classified according to the Centers for
Disease Control and Prevention definitions (15).
The patients’ levels of comprehension of the ARV
prescription were assessed using the following six items:
drug name, dosage, administration frequency, use precau-
tions or situations demanding special surveillance, side
effects, and dietary guidance. Scores indicating the patients’
levels of comprehension of their ARV prescriptions were
obtained using a latent trait model, estimated with Item
Response Theory (IRT) (16), based on the concordance
between each patient’s answer and the previously pub-
lished written prescription (17). For this analysis, each score
was categorized as sufficient or insufficient, based on the
median of participant scores. An understanding of medical
or pharmaceutical orientation was self-reported and cate-
gorized as follows: sufficient (high or complete), insufficient
(median, low or none), or did not receive orientation.
The duration between the initial HIV test and the first
ARV prescription and the time between the first medical
visit and ARV prescription were categorized using the
median points. Age was assessed as a continuous variable.
Adverse reactions were defined as any effects or undesir-
able symptoms reported by the patients over the study
period that were attributed to the ARV drug. Symptoms of
anxiety and depression were evaluated at baseline using the
Hospital Anxiety and Depression Scale (HADS) (18).
Quality of life was evaluated using the brief version of the
World Health Organization Quality of Life instrument
(WHOQOL-bref) (19). We used a global perception of
quality of life that classified the participants’ quality of life
into the following five categories: ‘very poor’, ‘poor’,
‘neither poor nor good’, ‘good’, and ‘very good’. For the
purposes of analysis, the data were dichotomized into two
categories, including those who classified their quality of
life as ‘very poor’, ‘poor’, and ‘neither poor nor good’,
compared to those who reported a ‘good’ or ‘very good’
quality of life (20).
The self-reported measurement of adherence was defined
as the number of prescribed doses of each ARV drug taken
during the three days prior to each follow-up visit. Only the
first occurrence of non-adherence was assessed, and it was
defined as the intake of less than 95% of the prescribed
number of doses. All analyses were stratified by gender, and
the times to non-adherence were estimated using the
Kaplan-Meier method and the Log-rank test.
The strength of association between selected exposure
variables and the first episode of non-adherence was
estimated by the relative hazard (RH) with 95% confidence
interval, obtained from Cox’s proportional hazard model for
both univariate and multivariate gender-stratified analyses.
Variables with p-values equal to or less than 0.20 were
included in the final multivariate model with a subsequent
sequential deletion. The level of significance required for
inclusion in the final model was 0.05 to better ascertain
potential confounders. A likelihood ratio test was used to
compare all models, and the proportional hazard assump-
tion was assessed by checking the parallelism of the log-log
survival curves and the Schoenfeld test.
& RESULTS
Among 306 participants, 199 (65.0%) were male, and 107
were female. Descriptive characteristics are presented in
Table 1. Higher proportions of women reported only basic
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Table 1 - Selected descriptive characteristics among 306 participants (199 men and 107 women), Belo Horizonte (MG),
2001-2002.
Characteristics Total Men Women
na (%) na (%) na (%)
SOCIODEMOGRAPHICS
Age (years)
.33 148 (48.4) 99 (49.8) 49 (45.8)
#33 158 (51.6) 100 (50.2) 58 (54.2)
Race
Non-white 218 (74.4) 137 (72.5) 81 (77.9)
White 75 (25.6) 52 (27.5) 23 (22.1)
Schooling (years)
#4 83 (27.2) 39 (19.7) 44 (41.1)
4-8 85 (27.9) 61 (30.8) 24 (22.4)
$8 137 (44.9) 98 (49.5) 39 (36.5)
Marital status
Single/Divorced/Widowed 198 (64.7) 135 (67.8) 63 (58.9)
Married/Stable union 108 (35.3) 64 (32.2) 44 (41.1)
Individual income in last month
Yes 179 (58.9) 123 (62.1) 56 (52.8)
No 125 (41.1) 75 (37.9) 50 (47.2)
Job schedule
Unfixed 59 (19.3) 46 (23.1) 13 (12.1)
Fixed 137 (44.8) 100 (50.3) 37 (34.6)
Unemployed 110 (36.0) 53 (26.6) 57 (53.3)
BEHAVIOR
Disclosure of HIV status
Yes 255 (86.4) 167 (85.6) 88 (88.0)
No 40 (13.6) 28 (14.4) 12 (12.0)
Alcohol use in month prior to baseline interview
Yes 111 (37.6) 78 (40.0) 33 (33.0)
No 184 (62.4) 117 (60.0) 67 (67.0)
Current tobacco use
Yes 101 (34.2) 75 (38.5) 26 (26.0)
No 194 (65.8) 120 (61.5) 74 (74.0)
Lifetime injection drug use
Yes 17 (5.8) 15 (7.7) 2 (2.0)
No 278 (94.2) 180 (92.3) 98 (98.0)
Lifetime illicit drug use
Yes 83 (28.1) 74 (38.0) 9 (9.0)
No 212 (71.9) 121 (62.0) 91 (91.0)
HEALTH SERVICES
Recruitment site
CTR/DIP 248 (81.1) 158 (79.4) 90 (84.1)
HEM 58 (18.9) 41 (20.6) 17 (15.9)
Difficulty in searching for HIV service
Yes 27 (9.2) 20 (10.3) 7 (7.1)
No 266 (90.8) 174 (89.7) 92 (92.9)
Number of attended HIV health service
Only one 227 (77.0) 151 (77.4) 76 (76.0)
More than one 68 (23.0) 44 (22.6) 24 (24.0)
Psychological support
Yes 16 (5.4) 10 (5.1) 6 (6.1)
No 278 (94.6) 85 (94.9) 93 (93.9)
Understanding of medical counseling
Sufficient 212 (69.7) 143 (72.2) 69 (65.1)
Insufficient 76 (25.0) 44 (22.2) 32 (30.2)
Did not receive 16 (5.3) 11 (5.6) 5 (4.7)
Understanding of pharmaceutical counseling
Sufficient 247 (80.7) 160 (80.4) 87 (81.3)
Insufficient 33 (10.8) 23 (11.6) 10 (9.4)
Did not receive 26 (8.5) 16 (8.0) 10 (9.4)
Understanding of ART prescription
Sufficient 152 (49.7) 99 (49.8) 53 (49.5)
Insufficient 154 (50.3) 100 (50.2) 54 (50.5)
CLINICAL
Number of prescribed pills/day
,7 134 (43.8) 85 (42.7) 49 (45.8)
7-12 122 (39.9) 85 (42.7) 37 (34.6)
.12 50 (16.3) 29 (14.6) 21 (19.6)
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levels of schooling (41.1%) and unemployment (53.3%)
compared to men (19.7% and 26.6%, respectively), whereas
men reported a higher proportion of lifetime illicit drug use
(38.0%) compared to women (9.0%). There were no marked
differences between genders with regard to health service
characteristics. However, clinical characteristics indicated
that women exhibited a longer duration between the HIV
test and the first ART prescription and between the first
medical visit and the first ART prescription. Furthermore,
women reported less positive self-perceived quality of life
(49.5%) than men (62.7%) and higher baseline anxiety
(47.0%) and depression symptoms (i.e., moderate-severe)
(34.0%) compared to men (29.5% and 15.5%, respectively).
The cumulative incidence of non-adherence was 34.6% (95%
CI = 29.5%-40.1%), including 29.7% (95% CI = 23.6%-36.3%)
among men and 43.9% (95% CI = 34.8%-53.4%) among
women (p= 0.01). A significant difference in non-adherence
survival Kaplan-Meier curves was identified between men
and women (Log-Rank Test: p= 0.038) (Figure 1). The
median time to the first episode of non-adherence was a
shorter duration for women (272 days) than men (327 days).
For men, univariate analyses (Table 2) indicated that non-
adherence was associated (p,0.05) with the following
factors: alcohol use in the month prior to the baseline
interview, lifetime injection drug use, lifetime illicit drug
use, self-reported difficulty with ART, baseline TCD4+
lymphocyte count ,200/mm3, five or more adverse reac-
tions reported, a longer duration between the HIV test and
the first ART prescription, a longer time between the first
medical visit and the first ART prescription, poorer self-
perceived quality of life, and the presence of moderate/
severe symptoms of anxiety or depression. For women,
univariate analyses indicated associations (p,0.05) with
alcohol use in the month prior to the baseline interview,
current tobacco use, and lifetime illicit drug use.
The final multivariate model is shown in Table 3. The
results indicated that self-reported difficulty of ART
(p= 0.002), five or more adverse reactions reported
(p= 0.007), and a longer duration between the HIV test
and the first ART prescription (p= 0.002) were indepen-
dently associated with increased risk of non-adherence
among male participants. In contrast, being married or in a
stable union (p= 0.022), alcohol use in the month prior to the
baseline interview (p= 0.046), current tobacco use (p= 0.005),
and a longer duration between the HIV test and the first
ART prescription (p= 0.028) were associated with increased
risk of non-adherence among female participants.
& DISCUSSION
In this analysis, the high incidence of non-adherence was
1.5 times greater among women compared to men. This
finding is consistent with studies reporting poorer adher-
ence among women that have significant differences
identified between genders (2,21-22). However, other
studies have failed to find a significant association between
gender and ARV adherence (11-12,23), and yet another
study reported higher adherence rates among women (13).
These discordant results may be due to methodological
distinctions, sample differences, or sociocultural divergence.
A literature review conducted on the adherence to ART in
developed countries and spanning from 2000-2011 was
conducted to determine whether the prevalence of non-
adherence varied by gender (24). The authors found that,
when using higher cutoff points (100% and 95%), women
exhibited a lower mean proportional adherence than men
Characteristics Total Men Women
na (%) na (%) na (%)
Self-reported difficulty of antiretroviral treatment
Low 141 (47.8) 94 (48.2) 47 (47.0)
High 154 (52.2) 101 (51.8) 53 (53.0)
Clinical classification
Symptomatic (B-C) 168 (56.8) 110 (57.3) 58 (55.8)
Asymptomatic (A) 128 (43.2) 82 (42.7) 46 (44.2)
Baseline TCD4+ lymphocyte count
,200/mm3 160 (58.8) 103 (59.5) 57 (57.6)
$200/mm3 112 (41.2) 70 (40.5) 42 (42.4)
Number of adverse reactions reported
,3 84 (27.5) 58 (29.3) 26 (24.3)
$3 221 (72.5) 140 (70.7) 81 (75.7)
Time between HIV test and first ART prescription
,113 days 152 (49.7) 111 (55.8) 41 (38.3)
$113 days 154 (50.3) 88 (44.2) 66 (61.7)
Time between first medical visit and first ART prescription
,43 days 144 (47.1) 103 (51.8) 41 (38.3)
$43 days 162 (52.9) 96 (48.2) 66 (61.7)
Self-perceived quality of life
Good 170 (58.2) 121 (62.7) 49 (49.5)
Poor 122 (41.8) 72 (37.3) 50 (50.5)
Baseline anxiety symptoms
None-mild 189 (64.5) 136 (70.5) 53 (53.0)
Moderate-severe 104 (35.5) 57 (29.5) 47 (47.0)
Baseline depression symptoms
None-mild 229 (78.2) 163 (84.5) 66 (66.0)
Moderate-severe 64 (21.8) 30 (15.5) 34 (34.0)
a Total for each variable differs as a result of missing values.
Table 1 - Continued.
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across all measurements. In contrast, lower cutoff points
(90% and 80%) indicated that women reported a higher
mean proportional adherence across the majority of
measurements. Although the authors concluded that these
findings suggested that female gender status often predicts
lower adherence, they emphasized that differences in
methodology may account for these contradictory results.
Distinct gender differences were observed in our results.
The only variable represented in the multivariate model for
both men and women was the association of non-adherence
with a longer duration between the HIV test result and the
first ARV prescription. This delay in treatment initiation is
concerning and can be the result of either the patient’s
difficulty in accepting the diagnosis and beginning treat-
ment or a reduced perception of the necessity of treatment
due to a lack of symptoms. The follow-up protocol for
individuals living with HIV requires that they return to the
health service for medical consultations every six months on
average. Moreover, HIV referral services tend to be over-
loaded with patients, and priority is usually given to those
with symptoms or more severe clinical conditions (25).
However, people living with HIV who are asymptomatic
tend to have less awareness of the disease and may not
perceive the seriousness of the AIDS threat (26). This
perception potentially results in poor and delayed searches
for care, despite the established capabilities and significant
investments made by the Brazilian Health System to help
diagnose, treat, and care for people living with HIV and
AIDS. We emphasize the need to implement counseling and
create alternative facilities for ambulatory care and treat-
ment (27).
Among men, self-reported difficulty with ART was a
predictor of non-adherence. To acquire a behavior, such as
adherence to ARV therapy, an individual needs to believe
that benefits of the behavior compensate for the potential
difficulties (28).
Consistent with the literature, our results indicated that
clinical factors such as adverse reactions have been
consistently associated with non-adherence (5). Adverse
reactions are common with ARV therapy, especially among
patients initiating treatment (3,10-12,22,29-30).
Among female participants, we determined that marital
status, including being married or in a stable union, was
associated with poor adherence. Potential explanations for
this finding include differences in health service attendance
given the responsibility to manage one’s home and children
(30). Health professionals from HIV referral services must
understand and involve the family and nurture social
relationships, with the aim of achieving and maintaining
high levels of adherence to ART for this particular
population (31). In addition to biological differences,
women with HIV often balance multiple roles, have limited
access to healthcare, report less household income, and
express other concerns that are not typically shared by HIV-
positive men (32).
Finally, our results emphasized that the behavioral
characteristics that can be modified after the initiation of
ART may be critical for the early adoption of adherent
behavior. The analysis indicated that, among women,
alcohol use was significantly associated with non-adher-
ence. These findings are consistent with the literature (11-
12), thereby suggesting that alcohol use may disproportio-
nately impact ARV adherence in women. Furthermore,
alcohol use is highly prevalent among individuals with
HIV/AIDS (21,31). A systematic review of the literature
indicated that, among individuals with HIV/AIDS, alcohol
use disorders are related to decreased ART adherence and
to poorer HIV treatment outcomes (31). Other studies
support the correlation with alcohol dependence in
women, which is thought to partially reflect the relative
behavior frequency in relation to male participants (11-12).
A separate study conducted between 1999 and 2004 using
two cohorts of women also indicated that alcohol use
(including binging and heavy and low consumption)
reduced adherence (33).
Our findings also indicated that tobacco use among
women was associated with non-adherence. This result is
corroborated by the literature, which has highlighted that
increased tobacco consumption soon after initiation of ART
was related with subsequent non-adherence (34). Similarly,
nicotine dependence appears to be related to non-adherence
in the context of other substance use behavior, and
depression may, in part, mediate the relationship between
tobacco use and ART non-adherence (34-35). Thus, in
addition to other health implications due to tobacco use,
Figure 1 - Time to non-adherence (Kaplan-Meier curves) by gender, Belo Horizonte (MG), 2001-2002.
Gender differences in ART non-adherence in Brazil
Bonolo PF et al.
CLINICS 2013;68(5):612-620
616
Table 2 - Univariate analysis of the first episode of ART non-adherence among 306 participants (199 men and 107




(95% CI) b p-value N (%) a
Relative hazard
(95% CI) b p-value
SOCIODEMOGRAPHICS
Age (years)
.33 28 (28.3) 1.00 20 (40.8) 1.00
#33 31 (31.0) 1.08 (0.65-1.80) 0.778 27 (46.6) 1.25 (0.70-2.22) 0.459
Race
White 14 (26.9) 1.00 8 (34.8) 1.00
Non-white 43 (31.4) 1.32 (0.72-2.42) 0.371 37 (45.7) 1.49 (0.69-3.20) 0.307
Schooling (years)
$8 26 (26.5) 1.00 16 (41.0) 1.00
4-8 18 (29.5) 1.29 (0.71-2.37) 0.402 11(45.8) 1.28 (0.59-2.76) 0.531
#4 15 (38.5) 1.67 (0.88-3.16) 0.117 20 (45.5) 1.30 (0.67-2.51) 0.437
Marital status
Single/Divorced 42 (31.1) 1.00 23 (36.5) 1.00
Married/Stable union 17 (26.6) 0.88 (0.50-1.55) 0.655 24 (54.6) 1.59 (0.90-2.82) 0.113
Individual income in last month
Yes 33 (26.8) 1.00 22 (39.3) 1.00
No 26 (34.7) 1.38 (0.83-2.31) 0.219 25 (50.0) 1.35 (0.76-2.40) 0.302
Job schedule
Unfixed 11 (23.9) 1.00 3 (23.1) 1.00
Fixed 28 (28.0) 1.23 (0.61-2.48) 0.555 16 (43.2) 1.58 (0.46-5.43) 0.468
Unemployed 20 (37.7) 1.77 (0.85-3.69) 0.131 28 (49.1) 2.04 (0.62-6.71) 0.241
BEHAVIOR
Disclosure of HIV status
Yes 50 (29.9) 1.00 41 (46.6) 1.00
No 8 (28.6) 0.87 (0.41-1.84) 0.720 3 (25.0) 0.42 (0.13-1.34) 0.143
Alcohol use in month prior to baseline interview
No 29 (24.8) 1.00 25 (37.3) 1.00
Yes 29 (37.2) 1.73 (1.03-2.89) 0.038* 19 (57.6) 1.97 (1.08-3.59) 0.026*
Current tobacco use
No 36 (30.0) 1.00 26 (35.1) 1.00
Yes 22 (29.3) 1.12 (0.66-1.91) 0.672 18 (69.2) 2.53 (1.39-4.63) 0.003*
Lifetime injection drug use
No 50 (27.8) 1.00 42 (42.9) 1.00
Yes 8 (53.3) 2.36 (1.12-5.00) 0.025* 2 (100.0) 2.73 (0.66-11.3) 0.166
Lifetime illicit drug use
No 29 (24.0) 1.00 35 (38.5) 1.00
Yes 29 (39.2) 1.91 (1.14-3.21) 0.014* 9 (100.0) 3.33 (1.58-6.98) 0.002*
HEALTH SERVICES
Recruitment site
CTR/DIP 52 (32.9) 1.00 39 (43.3) 1.00
HEM 7 (17.1) 0.55 (0.25-1.21) 0.135 8 (47.1) 1.31 (0.61-2.81) 0.488
Difficulty in searching for HIV service
No 48 (27.6) 1.00 43 (46.7) 1.00
Yes 10(50.0) 1.90 (0.96-3.77) 0.066 1 (14.3) 0.23 (0.03-1.63) 0.140
Number of attended HIV health service
Only one 47 (31.1) 1.00 36 (47.4) 1.00
More than one 11 (25.0) 0.74 (0.39-1.43) 0.376 8 (33.3) 0.57 (0.27-1.24) 0.156
Psychological support
Yes 2 (20.0) 1.00 1 (16.7) 1.00
No 56 (30.3) 1.63 (0.40-6.71) 0.497 43 (46.2) 3.12 (0.43-22.7) 0.261
Understanding of medical counseling
Sufficient 42 (29.4) 1.00 27 (39.1) 1.00
Insufficient 15 (34.1) 1.03 (0.57-1.86) 0.920 16 (50.0) 1.36 (0.73-2.52) 0.335
Did not receive 2 (18.2) 0.62 (0.15-2.56) 0.507 4 (80.0) 2.33 (0.81-6.68) 0.116
Understanding of pharmaceutical counseling
Sufficient 48 (30.0) 1.00 39 (44.8) 1.00
Insufficient 6 (26.1) 0.70 (0.30-1.64) 0.416 5 (50.0) 1.02 (0.40-2.59) 0.970
Did not receive 5 (31.3) 1.04 (0.41-2.62) 0.932 3 (30.0) 0.63 (0.19-2.03) 0.435
Understanding of ART prescription
Sufficient 30 (30.3) 1.00 20 (37.7) 1.00
Insufficient 29 (29.0) 0.98 (0.58-1.63) 0.923 27 (50.0) 1.47 (0.82-2.62) 0.194
CLINICAL
Number of prescribed pills/day
,7 20 (23.5) 1.00 18 (36.7) 1.00
7-12 28 (32.9) 1.35 (0.76-2.41) 0.308 17 (46.0) 1.15 (0.59-2.24) 0.674
.12 11 (37.9) 1.41 (0.67-2.94) 0.363 12 (57.1) 1.61 (0.77-3.34) 0.204
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particularly in women, more interventional studies are
needed to focus on smoking and non-adherence.
In conclusion, this gender analysis indicated that social,
behavioral, clinical, and health service characteristics asso-
ciated with non-adherence at the beginning of ART are
potentially different among women and men. Whereas
among men, these factors directly related to the treatment
per se, i.e., adverse reactions and self-reported difficulty, the
non-adherence among women was more clearly explained
by demographic (i.e., marital status) and behavioral
characteristics (i.e., alcohol, tobacco use). We should also
note that the time to reported non-adherence among women
was significantly shorter than that of men, thereby




(95% CI) b p-value N (%) a
Relative hazard
(95% CI) b p-value
Self-reported difficulty of antiretroviral treatment
Low 15 (16.0) 1.00 19 (40.4) 1.00
High 44 (43.6) 2.89 (1.61-5.20) ,0.001* 26 (49.1) 1.26 (0.70-2.27) 0.447
Clinical classification
Symptomatic (B-C) 30 (27.3) 1.00 21 (36.1) 1.00
Asymptomatic (A) 29 (35.4) 1.35 (0.81-2.26) 0.247 23 (50.0) 1.50 (0.83-2.72) 0.176
Baseline TCD4+ lymphocyte count
, 200/mm3 19 (18.5) 1.00 24 (42.1) 1.00
$ 200/m m3 29 (41.4) 2.56 (1.44-4.58) 0.002* 19 (45.2) 1.11 (0.61-2.03) 0.741
Number of adverse reactions reported
,5 20 (18.4) 1.00 20 (40.0) 1.00
$5 38 (42.7) 2.30 (1.33-3.95) 0.003* 27 (47.4) 1.20 (0.67-2.14) 0.543
Time between HIV test and first ART prescription
,113 days 23 (20.7) 1.00 13 (31.7) 1.00
$113 days 36 (40.9) 2.55 (1.49-4.37) 0.001* 34 (51.5) 1.81 (0.96-3.44) 0.068
Time between first medical visit and first ART
prescription
, 43 days 23 (22.3) 1.00 15 (36.6) 1.00
$ 43 days 36 (37.5) 1.90 (1.13-3.21) 0.016* 32 (48.5) 1.41 (0.76-2.60) 0.275
Self-perceived quality of life
Good 29 (24.0) 1.00 23 (46.9) 1.00
Bad 29 (40.3) 1.87 (1.12-3.14) 0.017* 20 (40.0) 0.81 (0.44-1.48) 0.491
Baseline anxiety symptoms
None-mild 33 (24.3) 1.00 21 (39.6) 1.00
Moderate-severe 25 (43.9) 1.93 (1.15-3.25) 0.013* 23 (48.9) 1.27 (0.70-2.30) 0.425
Baseline depression symptoms
None-mild 42 (25.8) 1.00 27 (40.9) 1.00
Moderate-severe 16 (53.3) 1.95 (1.10-3.47) 0.023* 17 (50.0) 1.36 (0.74-2.50) 0.322
aNumber and proportion of non-adherence.
bRelative hazard obtained from Cox’s proportional model with confidence interval.
Table 2 - Continued.
Table 3 - Relative hazard with 95% confidence interval obtained from multivariate analysis of the first episode of ART
non-adherence among 306 participants (199 men and 107 women), Belo Horizonte (MG), 2001-2002.
Men Women
Characteristics Relative hazard (95% CI) p-value Relative hazard (95% CI) p-value
Marital status
Single/Divorced - 1.00
Married/Stable union - - 2.01 (1.10-3.64) 0.022
Alcohol use in month prior to baseline interview
No - 1.00
Yes - - 1.86 (1.01-3.43) 0.046
Current tobacco use
No - 1.00
Yes - - 2.40 (1.30-4.41) 0.005
Self-reported difficulty of antiretroviral treatment
Low 1.00 -
High 2.53 (1.40-4.56) 0.002 - -
Number of adverse reactions reported
,5 1.00 -
$5 2.11 (1.22-3.63) 0.007 - -
Time between HIV test and first ART prescription
,113 days 1.00 1.00
$113 days 2.38 (1.37-4.12) 0.002 2.22 (1.09-4.51) 0.028
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treatment begins. Early intervention strategies to improve
adherence should focus on these differences and on an
integrated assessment of clinical, counseling, social, and
work support, while facilitating access to health services.
However, despite the evidence we have presented, addi-
tional studies are required to better ascertain the gender
differences in non-adherence so that effective measures can
be incorporated into the care of individuals living with HIV
who use public services in Brazil. Despite the evidence
provided by this analysis, further studies are still needed to
address these gaps in knowledge and to better conceptua-
lize gender differences in factors associated with non-
adherence in AIDS public referral centers, with the ultimate
aim of improving care and reducing the barriers to strong
treatment adherence.
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